Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 2Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Sarcoma 1Peritoneal Neoplasms 1Pancreatic Neoplasms 1Neuroblastoma 1Neoplasm Metastasis 1HER2 Positive Esophagogastric Cancer 1Glioblastoma 1Esophageal Squamous Cell Carcinoma 1Colorectal Neoplasms 1Cholangiocarcinoma 1Carcinoma, Non-Small-Cell Lung 1Advanced Esophageal Cancer 1

Interventions

Gemcitabine 58Cisplatin 32Oxaliplatin 28Fluorouracil 21lenvatinib 19durvalumab 18Capecitabine 17Leucovorin 15tislelizumab 10pembrolizumab 10apatinib 9Floxuridine 8Specimen Handling 7Panitumumab 7Magnetic Resonance Spectroscopy 7Albumin-Bound Paclitaxel 7sintilimab 6pemigatinib 6Radiotherapy 6Irinotecan 6Drug Therapy 6Biopsy 6tremelimumab 5regorafenib 5olaparib 5camrelizumab 5Taxes 5S 1 (combination) 5Nivolumab 5Folfox protocol 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Cholangiocarcinoma × Combined Modality Therapy × Clear all
NCT04413734 2020-06-04

Combination of Anti-PD-1 Antibody and Chemotherapy for Unresectable Intrahepatic Cholangiocarcinoma

Zhejiang University

Phase 2 Unknown
120 enrolled
Gastrointestinal

Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡